You are here
scPharmaceuticals Inc. Reports Second Quarter 2018 Financial Results and Provides Business Update
Request for Type A meeting was granted by the U.S. Food and Drug Administration to discuss the Complete Response Letter received in June 2018
Balance sheet remains strong with over $100 million in cash
BURLINGTON, Mass., Aug. 14, 2018 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs, today announced financial results for the second quarter ended June 30, 2018 and provided a business update.
“Since receiving the Complete Response Letter for FUROSCIX® from the U.S. Food and Drug Administration in June, we have been working to address the Agency’s questions and were granted a Type A Post-Action Meeting, scheduled for September 24, 2018,” said John Tucker, president and chief executive officer of scPharmaceuticals. “We look forward to meeting with the FDA to discuss the next steps. We remain committed to the development and commercialization of FUROSCIX and plan to update investors following receipt of minutes from our meeting with the FDA.”
- Granted Type A Post-Action Meeting with the FDA. On June 13, 2018, scPharmaceuticals announced the Company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the 505(b)(2) application for FUROSCIX, a treatment candidate for edema, or fluid overload, in patients with heart failure. The Company submitted a request to the FDA and was granted a Type A Post-Action Meeting, scheduled for September 24, 2018. scPharmaceuticals believes the upcoming meeting will provide an opportunity to define the pathway and timing to re-submit the NDA.
- Organizational restructuring in place to ensure financial flexibility. Since receiving the CRL, scPharmaceuticals has implemented a companywide restructuring to align the workforce with the upcoming needs of the business and focus on activities essential to addressing the CRL and FUROSCIX development. Following the restructuring, the company has 24 full time employees.
- Appointed three directors with deep financial, industry and regulatory experience. Frederick Hudson, 37 years at KPMG and lead partner of KPMG’s Mid-Atlantic region healthcare audit practice; Minnie Baylor-Henry, 20 years regulatory affairs with Johnson & Johnson and with the FDA; and Dr. Mason Freeman, 5AM Ventures and Massachusetts General Hospital, all joined the scPharmaceuticals Board. Each of the three new directors brings to the Company a deep understanding of the biopharmaceutical industry in key areas including audit, clinical, and regulatory strategy that will contribute to scPharmaceuticals’ efforts as it works with the FDA and moves toward the re-submission and potential approval of FUROSCIX.
Second Quarter 2018 Financial Results and Financial Guidance
scPharmaceuticals reported a net loss of $9.9 million in the second quarter of 2018 compared to $6.5 million for the second quarter period of 2017. The increase in net loss for the second quarter ended June 30, 2018, was largely due to costs associated with increased headcount, the expansion of the Company’s commercial organization, and costs incurred as a public company.
Research and development expenses were $4.9 million for the second quarter of 2018 compared to $4.1 million for the comparable period in 2017. The increase in research and development expenses for the quarter ended June 30, 2018, was largely due to increased headcount and costs associated with clinical initiatives.
General and administrative expenses were $5.0 million for the second quarter of 2018 compared to $2.4 million for the comparable period in 2017. The increase in general and administrative expenses for the year was primarily due to increased headcount, the expansion of the Company’s commercial organization, and costs incurred as a public company.
scPharmaceuticals ended the second quarter of 2018 with $101.0 million in cash compared to $118.5 million as of December 31, 2017. This change reflects the ongoing investment in product and clinical development, as well as the costs incurred in the Company’s transition to a public company and costs associated with preparing for the potential commercialization of FUROSCIX.
Based on its current operating plan, scPharmaceuticals expects year end 2018 cash and cash equivalents and investment securities to be approximately $80 - $85 million and forecasts 2019 expenditures of $8 - $10 million per quarter.
FUROSCIX is a proprietary furosemide solution formulated to a neutral pH to allow for subcutaneous infusion via the patented Infusor, a wearable, pre-programed drug delivery system that is applied to the abdomen for subcutaneous drug administration. FUROSCIX is under review by the FDA for treatment of edema, or fluid overload, in patients with heart failure. FUROSCIX has the potential to provide an outpatient alternative to IV furosemide for the treatment of worsening heart failure due to edema that would typically require hospitalization.
scPharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that reduce healthcare costs and improve health outcomes. The Company develops products for the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit scPharmaceuticals.com.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding the Company’s new drug application for FUROSCIX; the Company’s planned actions in response to the FDA’s Complete Response Letter, including the timing of any future public announcement; the outcome of the Company's Type A Post-Action Meeting with the FDA; the benefits of the Company’s restructuring, including the sufficiency of its existing resources; the potential timing and advancement of our ongoing or planned clinical trials and investigator-sponsored studies; the announcement of data from these trials and studies; and the Company’s financial condition and cash runway. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company may not be able to remediate the deficiencies identified by the FDA in the Complete Response Letter or receive regulatory approval of FUROSCIX or any other product candidates or, if approved, successfully commercialize such products, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, and the risk that the results of previously conducted studies will not be repeated or observed in ongoing or future studies involving our product candidates. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in the Company’s most recent Annual Report on Form 10-K on file with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.
Troy Ignelzi, scPharmaceuticals Inc.
Christopher F. Brinzey, Westwicke Partners
|Unaudited Statements of Operations and Comprehensive Loss|
|(in thousands, except share and per share data)|
|THREE MONTHS ENDED|
|SIX MONTHS ENDED|
|Research and development||$||4,145||$||4,855||$||7,030||$||8,903|
|General and administrative||2,374||5,049||4,448||9,700|
|Total operating expenses||6,519||9,904||11,478||18,603|
|Loss from operations||(6,519||)||(9,904||)||(11,478||)||(18,603||)|
|Other income (expense)||57||(11||)||67||(53||)|
|Net loss and comprehensive loss||$||(6,536||)||$||(9,850||)||$||(11,448||)||$||(18,582||)|
|Net loss per share, basic and diluted||$||(6.09||)||$||(0.53||)||$||(10.68||)||$||(1.00||)|
|Weighted—average common shares outstanding, basic and diluted||1,072,940||18,549,978||1,071,822||18,542,745|
|Unaudited Balance Sheet Data|
|Cash and restricted cash||$||118,480||$||100,950|
|Total stockholders’ equity||105,997||88,592|